Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.

By T. Takano, Yuichiro Ohe, H. Sakamoto, K. Tsuta, Y. Matsuno, U. Tateishi, Seiichiro Yamamoto, H. Nokihara, N. Yamamoto, I. Sekine and 5 more. Journal of Clinical Oncology, 2005

706 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f52c920dadfa6fafd5ce50b17819b1656f5f01fd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. Akinori Sarai
2. Hideaki Mizuno

Citations in the corpus

• Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. (2012, methodology): “Mutation analyses Genomic DNAs from all 226 lung adenocarcinomas were analyzed for EGFR and KRASmutations by the high-resolution melting method as described (23, 24).”
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors (2009, neutral): “In four single-arm studies of EGFR TKIs in patients with metastatic NSCLC, a significantly longer overall survival was observed in patients with EGFR mutations (Cortez-Funes et al., 2005; Han et al., 2005; Mitsudomi et al., 2005; Takano et al., 2005).”